<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04821687</url>
  </required_header>
  <id_info>
    <org_study_id>OGT001</org_study_id>
    <nct_id>NCT04821687</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PD</brief_title>
  <official_title>A Randomized, Parallel Group, Multicenter, Prospective, Open-label, Exploratory, Phase 4 Study to Evaluate the Add-on Effect of Opicapone 50 mg or Levodopa 100 mg as First Strategy for the Treatment of Wearing-off in Patients With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SK Chemicals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SK Chemicals Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Study to evaluate the add-on efficacy and safety of opicapone 50 mg or an extra dose of&#xD;
      L-DOPA 100 mg for the treatment of wearing-off in patients with PD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 17, 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hauser's diary</measure>
    <time_frame>Baseline, at 2 weeks, and 4 weeks</time_frame>
    <description>Change in absolute OFF-time and ON-time. Since this study is exploratory, there is no separate primary endpoint.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Opicapone 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Levodopa 100mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ongentys 50mg</intervention_name>
    <description>Opicapone 50mg will be added to current and stable therapy of L-DOPA/DDCI</description>
    <arm_group_label>Opicapone 50mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Madopar Tab. 125 or Perkin Tab. 25-100mg</intervention_name>
    <description>Madopar Tab. 125 or Perkin Tab. 25-100mg will be added to current and stable therapy of L-DOPA/DDCI</description>
    <arm_group_label>Levodopa 100mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosed with idiopathic PD according to the UK Parkinson's Disease Society Brain&#xD;
             Bank Clinical Diagnostic Criteria (2006) or according to the Movement Disorder Society&#xD;
             (MDS) Clinical Diagnostic Criteria (2015).&#xD;
&#xD;
          2. Disease severity Stage III (H&amp;Y staging) at ON.&#xD;
&#xD;
          3. Treated on a stable regimen for at least four weeks before screening with&#xD;
             immediate-release L-DOPA/DDCI, three to four intakes per day, and up to maximum daily&#xD;
             dose of 600mg L-DOPA.&#xD;
&#xD;
          4. Signs of wearing-off phenomenon with average total daily OFF-time while awake of at&#xD;
             least 1 hour, including the early morning pre-first dose OFF (i.e. the time between&#xD;
             wake-up and response to the first L-DOPA/DDCI dosage), despite optimal anti-PD therapy&#xD;
             (based on Investigator's assessment).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non-idiopathic PD (atypical Parkinsonism, secondary [acquired or symptomatic]&#xD;
             parkinsonism, Parkinson-plus syndrome.&#xD;
&#xD;
          2. Severe and/or unpredictable OFF periods, according to Investigator judgment.&#xD;
&#xD;
          3. Average total daily OFF-time while awake of &gt;5 hours, including the early morning&#xD;
             pre-first dose OFF, despite optimal anti-PD therapy (based on Investigator's&#xD;
             assessment).&#xD;
&#xD;
          4. Treatment with prohibited medication: entacapone, tolcapone, monoamine oxidase (MAO)&#xD;
             inhibitors (except selegiline up to 10 mg/day in oral formulation or 1.25 mg/day in&#xD;
             buccal absorption formulation, rasagiline up to 1 mg/day or safinamide up to 100&#xD;
             mg/day), apomorphine or antiemetics with antidopaminergic action (except domperidone)&#xD;
             within the last four weeks before screening.&#xD;
&#xD;
          5. Previous or planned (during the entire study duration) deep brain stimulation or&#xD;
             stereotactic surgery (e.g. pallidotomy, thalamotomy).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>SangKeun Choi</last_name>
    <phone>+82-2-2008-1926</phone>
    <email>okskchoi@sk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Anyang-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyeo-Il Ma</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COMT inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benserazide, levodopa drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

